AKT1 is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT3 is altered in 1.19% of peritoneal mesothelioma patients [2].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ARID1A is altered in 2.35% of peritoneal mesothelioma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BAP1 is altered in 49.41% of peritoneal mesothelioma patients [2].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CRKL is altered in 1.19% of peritoneal mesothelioma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FH is altered in 2.41% of peritoneal mesothelioma patients [2].

FH is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains FH status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

MTOR is altered in 2.3% of peritoneal mesothelioma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CA is altered in 2.15% of peritoneal mesothelioma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is altered in 1.08% of peritoneal mesothelioma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RICTOR is altered in 1.3% of peritoneal mesothelioma patients [2].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SDHA is altered in 1.23% of peritoneal mesothelioma patients [2].

SDHA is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHA status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHB is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHB status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHC is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHC status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHD is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

TSC1 is altered in 1.15% of peritoneal mesothelioma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].